Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

1, 9-Pyrazoloanthrones downregulate HIF-1α and sensitize cancer cells to cetuximab-mediated anti-EGFR therapy.

PloS one - 29 Dec 2010

Lu Yang, Li Xinqun, Lu Haiquan, Fan Zhen

Abstract excerpt

Cetuximab, a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR), is currently approved for the treatment of several types of solid tumors. We previously showed that cetuximab can inhibit hypoxia-inducible factor-1 alpha (HIF-1α) protein synthesis by inhibiting the activation of EGFR downstream signaling pathways including Erk, Akt, and mTOR. 1, 9-pyrazoloanthrone (1, 9 PA) is an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthracenes
Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hypoxia-Inducible Factor 1

Share to MAP Kinase Kinase 4

Share to Pyrazoles

Share to Ubiquitin

Share to Vascular Endothelial Growth Factor A

Source

Open in PubMed Open full text

Identifiers

PMID: 21209911
DOI: 10.1371/journal.pone.0015823
PMCID: PMC3012113

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

1, 9-Pyrazoloanthrones downregulate HIF-1α and sensitize cancer cells to cetuximab-mediated anti-EGFR therapy.PMID 21209911Read ↗

Hypoxia Inducible Factor-1a a Novel Molecular Target for 2-Aminopyrrole Derivative: Biological and Molecular Modeling StudySemantic proximity Read ↗

Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha.Semantic proximity Read ↗

A Novel Transcriptional Inhibitor Induces Apoptosis in Tumor Cells and Exhibits Antiangiogenic ActivitySemantic proximity Read ↗

HIF-1 Signaling in Drug Resistance to ChemotherapySemantic proximity Read ↗

HIF2α inhibition promotes p53 pathway activity, tumor cell death, and radiation responsesSemantic proximity Read ↗

Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.Semantic proximity Read ↗

HIF-dependent antitumorigenic effect of antioxidants in vivo.Semantic proximity Read ↗

Hypoxia-Mediated Down-Regulation of Bid and Bax in Tumors Occurs via Hypoxia-Inducible Factor 1-Dependent and -Independent Mechanisms and Contributes to Drug ResistanceSemantic proximity Read ↗

Hypoxia inducible factor-1α as a cancer drug targetSemantic proximity Read ↗

HIF-1α depletion results in SP1-mediated cell cycle disruption and alters the cellular response to chemotherapeutic drugsSemantic proximity Read ↗

In Vivo Topoisomerase I Inhibition Attenuates the Expression of Hypoxia-Inducible Factor 1α Target Genes and Decreases Tumor AngiogenesisSemantic proximity Read ↗

Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.